or Try an Advanced Search...

    Treatment Of Hepatitis Stocks List

    Symbol Grade Name % Change
    ENTA C Enanta Pharmaceuticals, Inc. 9.06
    VIR C Vir Biotechnology, Inc. 13.18
    AIM F AIM ImmunoTech Inc. 0.15
    HEPA F Hepion Pharmaceuticals, Inc. -3.95
    EIGR F Eiger BioPharmaceuticals, Inc. 0.00
    View As Page of Charts
    Related Industries: Biotechnology
    Related Stock Lists: Biotechnology Hepatitis B Infectious Diseases Treatment Of Hepatitis B Biopharmaceutical Cyclophilin Medicine Acid Alnylam Pharmaceuticals Cancer Carcinoma Chemical Compounds Chronic Fatigue Syndrome Chronic Liver Disease Chronic Liver Diseases Coronavirus Cyclopropanes Dimm Disease Drug Therapy

    Related ETFs - A few ETFs which own one or more of the above listed Treatment Of Hepatitis stocks.

    Symbol Grade Name Weight
    GERM C ETFMG Treatments Testing and Advancements ETF 3.48
    GNOM D Global X Genomics & Biotechnology ETF 1.38
    SBIO D ALPS Medical Breakthroughs ETF 0.93
    IDNA C iShares Genomics Immunology and Healthcare ETF 0.9
    BBC D Virtus LifeSci Biotech Clinical Trials ETF 0.69
    View all Treatment Of Hepatitis ETFs...
    Compare ETFs
    Compare GERM to GNOM Compare GNOM to BBC Compare GNOM to SBIO

        Treatment Of Hepatitis Stocks Recent News

        Date Stock Title
        May 3 VIR Vir Biotechnology, Inc. (NASDAQ:VIR) Q1 2024 Earnings Call Transcript
        May 3 VIR Vir Biotechnology Provides Some Hope For Its Beleaguered Shareholders
        May 3 ENTA Strong week for Enanta Pharmaceuticals (NASDAQ:ENTA) shareholders doesn't alleviate pain of five-year loss
        May 3 VIR Q1 2024 Vir Biotechnology Inc Earnings Call
        May 3 VIR Vir Biotechnology Inc (VIR) (Q1 2024) Earnings Call Transcript Highlights: Navigating ...
        May 3 VIR Vir Biotechnology, Inc. (VIR) Q1 2024 Earnings Call Transcript
        May 2 VIR Vir Biotechnology, Inc. (VIR) Reports Q1 Loss, Tops Revenue Estimates
        May 2 VIR Vir Biotechnology GAAP EPS of -$0.48 beats by $0.59, revenue of $56.38M beats by $44.67M
        May 2 VIR Vir Biotechnology Provides Corporate Update and Reports First Quarter 2024 Financial Results
        May 1 VIR Vir Biotechnology Q1 2024 Earnings Preview
        Apr 30 VIR Vir Biotechnology to Participate in the BofA Securities Healthcare Conference 2024
        Apr 30 ENTA Enanta Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
        Apr 30 ENTA Enanta Pharmaceuticals Announces the Appointment of Matthew P. Kowalsky as Chief Legal Officer
        Apr 29 ENTA Enanta Pharmaceuticals to Host Conference Call on May 6 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Second Quarter Ended March 31, 2024
        Apr 28 VIR With 53% ownership, Vir Biotechnology, Inc. (NASDAQ:VIR) boasts of strong institutional backing
        Related Industries: Biotechnology
        Related Stock Lists: Biotechnology Hepatitis B Infectious Diseases Treatment Of Hepatitis B Biopharmaceutical Cyclophilin Medicine Acid Alnylam Pharmaceuticals Cancer Carcinoma Chemical Compounds Chronic Fatigue Syndrome Chronic Liver Disease Chronic Liver Diseases Coronavirus Cyclopropanes Dimm Disease Drug Therapy
        Treatment Of Hepatitis

        Treatment for hepatitis depends on the type of hepatitis and the severity of the condition. Treatment may include medications, lifestyle changes, and in some cases, surgery. Common treatments for hepatitis include antiviral medications, immunosuppressants, interferon, and corticosteroids. In some cases, a liver transplant may be necessary.

        Browse All Tags